THT Biomaterials GmbH
“The Human Touch” (THT) Biomaterials GmbH was founded in 2020 with the goal of providing affordable, sustainable, and personalized medicine. By using human placenta tissue, a so-called medical waste, THT Biomaterials GmbH offers an innovative platform technology based on human-derived biomaterials. In particular, THT Biomaterials GmbH develops human placenta-derived extracellular matrix (ECM) proteins for different life sciences applications such as 2D/3D culture, organoid culture, organ-on-a-chip, and 3D bioprinting. Doing so, THT Biomaterials GmbH contributes not only to enhancing the translation of research into clinical applications but at the same time to reducing and replacing animal-derived materials in research (Directive 2010/63/EU).